Lupin announced Tuesday that it will incorporate the air propeller of the Honeywell solstice in its next -generation respiratory inhalers, becoming the first Indian pharmaceutical company to use this technology on scale.
The Association aims to transform respiratory care for asthma and patients with chronic obstructive pulmonary disease (COPD), while the significant reduction in environmental impact. HFO-1234ZE CGMP propeller can decrease greenhouse gas emissions by up to 99.9 percent compared to traditional propellers based on hydrofluorocarbon in dose inhalers presurized measures.
“The Lupin Association with Honeywell underlines our commitment to deliver high quality medicines while working towards a healthier and more sustainable future,” said Vinita Gupta, CEO of Lupine.
Jeff Dormo, president of the Honeywell Energy and Sustainability Solutions business, emphasized that Solstice Air will help to ensure that Lupine devices provide effective treatment while reducing the harmful emissions of greenhouse gases.
Ongoing negotiation
The terms of the agreement remain subject to negotiation and execution of definitive agreements between both companies.
Lupin operates worldwide with products distributed in more than 100 markets, maintaining a strong presence in India and the US. In multiple areas of therapy, including respiratory, cardiovascular and antidiabetic treatments. The company has 15 manufacturing sites and seven research centers worldwide, with more than 23,000 employees.
Lupin’s shares closed to ₹ 1,969.50, less ₹ 60.10 or 2.96 percent in the NSE.
Posted on May 20, 2025
